Valuation dashboard for CervoMed Inc. (CRVO) with P/E N/A, P/B 1.09, EV/EBITDA -0.03 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression.
Analysis Summary
Trailing-twelve-month margins: gross margin 100.0%, operating margin -96.6%, net margin -94.1%.
At the current price of $2.44, CRVO has negative trailing earnings (P/E not meaningful) and an ROE of -156.02%. Market capitalisation stands at $23M.
Balance sheet quality for CRVO: current ratio of 4.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.09 |
| EV / EBITDA | -0.03 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.80 |
| vs Current Price | -67.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CRVO | CervoMed Inc. | $23M | 1.09 | -156.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.44 |
| Market Cap | $23M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -156.02% |
| Return on Invested Capital | -135.73% |
| Return on Assets | -116.76% |
| Gross Margin | 100.00% |
| Operating Margin | -9661.43% |
| Net Margin | -9408.76% |
Related companies: ACET · ADAG · FBIO · GANX · LITS · NRXP · NTRB
Explore sector: Healthcare · Biotechnology
More sections of CRVO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks